Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GoPro Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while GoPro Inc trades at $0.59 (market cap $114.41M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 258.7× GoPro Inc's market cap. Which is the better fit depends on your goals.
| ALNY | GPRO | |
|---|---|---|
Market Cap | $29.60B | $114.41M |
Sector | Health | Technology |
52-Week High | $491.22 | $2.88 |
52-Week Low | $205.48 | $0.62 |
Enterprise Value | $27.56B | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
GoPro (GPRO) trades at $0.57, down 18.48% in the last session, reflecting ongoing operational challenges. The company shows deteriorating fundamentals with negative net income margins (-28.52%) and consecutive earnings misses. Technical indicators signal bearish momentum, while cash flow remains negative. Recent news highlights a strategic review process for potential sale alternatives as the company faces significant financial stress.
The outlook remains highly speculative with substantial execution risks. Investment opportunity hinges entirely on successful strategic alternatives, while risks include persistent cash burn, competitive pressures, and potential dilution from recent financing. The stock presents a binary outcome scenario dependent on corporate action success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
